Palvella Therapeutics, Inc. (PVLA) Operating Expenses (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Operating Expenses for 12 consecutive years, with $1.4 million as the latest value for Q4 2024.
- On a quarterly basis, Operating Expenses rose 102.6% to $1.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $11.2 million, a 6.01% decrease, with the full-year FY2024 number at $14.1 million, up 18.75% from a year prior.
- Operating Expenses was $1.4 million for Q4 2024 at Palvella Therapeutics, down from $5.1 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $31.3 million in Q3 2023 to a low of -$54.9 million in Q4 2023.
- A 5-year average of $11.9 million and a median of $17.2 million in 2020 define the central range for Operating Expenses.
- Peak YoY movement for Operating Expenses: crashed 416.14% in 2023, then skyrocketed 102.6% in 2024.
- Palvella Therapeutics' Operating Expenses stood at $14.3 million in 2020, then skyrocketed by 36.07% to $19.4 million in 2021, then fell by 10.68% to $17.4 million in 2022, then plummeted by 416.14% to -$54.9 million in 2023, then surged by 102.6% to $1.4 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Operating Expenses are $1.4 million (Q4 2024), $5.1 million (Q3 2024), and $2.9 million (Q2 2024).